Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E K Rowinsky

Showing results (71-80 of 159) with videos related to

Pageof 16
Sort By:
Cancer Research|August 15, 1989
Phase I and pharmacodynamic study of taxol in refractory acute leukemiasE K Rowinsky, P J Burke, J E Karp, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 19, 2003
A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignanciesG H Schwartz, A Patnaik, L A Hammond, et al.
Journal of the National Cancer Institute. Monographs|January 1, 1993
Hepatic metabolism and biliary excretion of Taxol in rats and humansB Monsarrat, P Alvinerie, M Wright, et al.
Cancer Chemotherapy and Pharmacology|October 11, 2001
Bioavailability of penclomedine and systemic exposure to 4-O-demethylpenclomedine in patients receiving oral and intravenous penclomedineS O'Reilly, N R Hartman, K M Bowling, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumorsE K Rowinsky, L B Grochow, S E Sartorius, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1994
Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic dataJ M Borkowski, M Duerr, R C Donehower, et al.
Journal of the National Cancer Institute|June 5, 1996
Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell linesS H Kaufmann, D Peereboom, C A Buckwalter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 1997
Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agentE K Rowinsky, G S Long, D A Noe, et al.
Investigational New Drugs|December 16, 1998
Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming unitsL L Siu, D D Von Hoff, A Rephaeli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 1998
A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignanciesM Hidalgo, G Rodriguez, J G Kuhn, et al.
Pageof 16

Showing results (71-80 of 159) with videos related to

Sort By:
Pageof 16
Cancer Research|August 15, 1989
Phase I and pharmacodynamic study of taxol in refractory acute leukemiasE K Rowinsky, P J Burke, J E Karp, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|April 19, 2003
A phase I study of bizelesin, a highly potent and selective DNA-interactive agent, in patients with advanced solid malignanciesG H Schwartz, A Patnaik, L A Hammond, et al.
Journal of the National Cancer Institute. Monographs|January 1, 1993
Hepatic metabolism and biliary excretion of Taxol in rats and humansB Monsarrat, P Alvinerie, M Wright, et al.
Cancer Chemotherapy and Pharmacology|October 11, 2001
Bioavailability of penclomedine and systemic exposure to 4-O-demethylpenclomedine in patients receiving oral and intravenous penclomedineS O'Reilly, N R Hartman, K M Bowling, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 1, 1996
Phase I and pharmacologic study of high doses of the topoisomerase I inhibitor topotecan with granulocyte colony-stimulating factor in patients with solid tumorsE K Rowinsky, L B Grochow, S E Sartorius, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1994
Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic dataJ M Borkowski, M Duerr, R C Donehower, et al.
Journal of the National Cancer Institute|June 5, 1996
Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell linesS H Kaufmann, D Peereboom, C A Buckwalter, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 1, 1997
Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agentE K Rowinsky, G S Long, D A Noe, et al.
Investigational New Drugs|December 16, 1998
Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming unitsL L Siu, D D Von Hoff, A Rephaeli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 26, 1998
A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignanciesM Hidalgo, G Rodriguez, J G Kuhn, et al.
Pageof 16